Accreditation Expired
The pathogenesis of IgAN and role of proteinuria
GlobalThe pathogenesis of IgAN, proteinuria, and novel treatments
Immunoglobulin A nephropathy, or IgAN, is a significant contributor to kidney failure. Without timely diagnosis and intervention, the disease can progress quickly.
In this 5 minute video, Professor Sydney Tang explores the pathogenesis of IgAN – including the role of proteinuria plays in its mechanisms – before discussing the importance of treating clinically meaningful proteinuria targets, guideline recommendations, and the therapies available to help patients achieve these targets.
Nephrologists and general practitioners
After completing this educational activity, learners will be able to explain the distinct pathogenesis of IgAN, including the role of proteinuria in these mechanisms, and the need to treat to clinically meaningful proteinuria targets
Type of affiliation / financial interest | Name of commercial company |
---|---|
Honoraria | Bayer AG, AstraZeneca, Boehringer Ingelheim, Novartis, GSK |
Consultant Fees | Eledon Pharmaceuticals |
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in collaboration with an independent steering committee; Travere Therapeutics had no influence on the content of this educational activity.
This module was accredited on the 2nd June 2023 and will expire on the 1st June 2024.
The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the ACHL and Liberum IME. ACHL is accredited by the ACCME to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning (ACHL) designates this enduring material for up to 0.25 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.
The American Medical Association (AMA) has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu
The content for this activity was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
The pathogenesis of IgAN, proteinuria, and novel treatments
Patogenesi della IgAN, proteinuria e nuovi trattamenti
Die Pathogenese der IgAN, Proteinurie und neue Behandlungsmöglichkeiten
Patogénesis de la IgA, proteinuria y nuevos tratamientos
Pathogenèse de l'IgAN, protéinurie et nouveaux traitements